tiprankstipranks
Trending News
More News >
Stereotaxis (STXS)
:STXS
Advertisement

Stereotaxis (STXS) AI Stock Analysis

Compare
327 Followers

Top Page

STXS

Stereotaxis

(NYSE MKT:STXS)

Rating:66Neutral
Price Target:
$3.00
▲(4.53% Upside)
Stereotaxis' stock score is driven by strong technical momentum and positive earnings call highlights, including significant revenue growth and strategic product launches. However, ongoing profitability challenges and a negative valuation score due to a negative P/E ratio and lack of dividend yield temper the overall score.
Positive Factors
Product Adoption
Magic is now in use in 30% of the company's accounts compared to 20% in Q1, indicating increased adoption and positive physician feedback.
Regulatory Approvals
The July US clearance of Magic Sweep is a big regulatory achievement and should be followed by several more key US and EU approvals before year-end.
Revenue Performance
Revenue for Q2 was $8.8M, up 95% from the prior year and up 18% from the prior quarter, beating the Street's $8.1M estimate.
Negative Factors
Cash Flow
STXS ended the quarter with cash and cash equivalents of $7.0M and no debt, and raised $12.5M via a direct offering, giving a pro forma cash balance of $18.8M.
Market Competition
The transformation to having a whole product portfolio inclusive of a more easily adoptable robot, high-margin disposables, new indications, and operating room connectivity solutions continues to progress.

Stereotaxis (STXS) vs. SPDR S&P 500 ETF (SPY)

Stereotaxis Business Overview & Revenue Model

Company DescriptionStereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company also provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane full-power x-ray system, including c-arm, powered table, motorized boom, and large high-definition monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. Stereotaxis, Inc. markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with Osypka AG to develop a magnetic ablation catheter using Stereotaxis' robotic technology. Stereotaxis, Inc. was incorporated in 1990 and is headquartered in Saint Louis, Missouri.
How the Company Makes MoneyStereotaxis generates revenue primarily through the sale of its robotic systems, disposable catheters, and software solutions. The company earns money from the initial sale of its Niobe® systems to hospitals and medical institutions, which is often accompanied by service agreements and maintenance contracts that provide ongoing revenue. Additionally, Stereotaxis benefits from recurring revenue through the sale of disposable catheters used in procedures performed with its robotic systems. Partnerships with hospitals and medical centers, as well as collaborations with other medical technology firms, also contribute to its earnings by expanding its customer base and enhancing its product offerings.

Stereotaxis Earnings Call Summary

Earnings Call Date:Aug 07, 2025
(Q2-2025)
|
% Change Since: |
Next Earnings Date:Nov 06, 2025
Earnings Call Sentiment Positive
The earnings call highlighted significant revenue growth and strategic progress with product launches and FDA clearances. However, ongoing operating losses and administrative challenges in Europe were noted as areas of concern. Overall, the positive developments outweigh the negatives.
Q2-2025 Updates
Positive Updates
Significant Revenue Growth
Revenue for the second quarter of 2025 totaled $8.8 million, a growth of 95% from $4.5 million in the prior year second quarter and a growth of 18% sequentially compared to $7.5 million in the first quarter of 2025.
Successful GenesisX and MAGiC Launches
Revenue recognition on the first GenesisX system and initial MAGiC sales in Europe contributed significantly to the quarter's financial performance.
FDA Clearance and Regulatory Progress
FDA clearance of the MAGiC Sweep high-density mapping catheter marked a major milestone, along with ongoing regulatory steps for GenesisX and other products.
Strategic Financing
Stereotaxis announced a registered direct financing for the sale of $12.5 million of its shares, with a first closing of $8.5 million completed in July, strengthening the balance sheet.
Strong Gross Margins on Recurring Revenue
Recurring revenue gross margin was 68% for the quarter.
Negative Updates
Continued Operating Loss
Operating loss for the second quarter of 2025 was $4 million, though reduced from $6 million in the previous year.
Negative Free Cash Flow
Negative free cash flow for the second quarter was $3.7 million compared to $3.1 million in the previous year.
Administrative Challenges in Europe
Administrative burdens and slow tender processes are impacting the rollout of MAGiC catheters in Europe.
Company Guidance
During the second quarter of 2025, Stereotaxis reiterated its revenue guidance for the full year, projecting double-digit growth. The company achieved a total revenue of $8.8 million, marking a 95% increase compared to the previous year's second quarter and an 18% sequential rise. System revenue reached $3 million, while recurring revenue was $5.8 million. Stereotaxis also highlighted the progress of its GenesisX system, which received CE Mark approval in Europe and is pending FDA clearance in the U.S. The introduction of new catheters, such as MAGiC Sweep, is expected to significantly boost revenue per procedure and expand the user base. Operating expenses for the quarter were $8.6 million, with adjusted operating expenses at $6 million. The company ended the quarter with $7 million in cash and announced a subsequent $12.5 million financing, bolstering its cash position to $18.8 million.

Stereotaxis Financial Statement Overview

Summary
Stereotaxis shows consistent revenue but struggles with profitability due to high operational costs, leading to negative net income. The balance sheet indicates balanced leverage but limited equity, while cash flow constraints highlight the need for improved cash management.
Income Statement
65
Positive
Stereotaxis has shown marginal revenue growth over the years but faces challenges in profitability. The gross profit margin remains robust at around 54.2% for 2024, but the company continues to operate at a net loss, with a net profit margin of -94.2% in 2024. This indicates high operational costs relative to revenue, leading to negative EBIT and EBITDA margins, which suggest a need for cost management and strategic improvements.
Balance Sheet
60
Neutral
The debt-to-equity ratio for 2024 stands at approximately 0.99, showing a balanced leverage profile. However, the equity ratio is relatively low at 13.0%, indicating limited asset backing by equity. The company’s return on equity is negative due to sustained losses, highlighting potential financial stability concerns.
Cash Flow
58
Neutral
Free cash flow has seen a slight improvement but remains negative, reflecting cash outflow challenges. The operating cash flow to net income ratio is unfavorable due to negative cash flows, indicating issues in converting revenue into cash. The free cash flow to net income ratio also highlights cash generation difficulties, requiring strategic cash flow management.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue27.51M26.92M26.77M28.15M35.02M26.63M
Gross Profit14.69M14.59M14.86M18.47M23.23M18.97M
EBITDA-24.62M-23.77M-21.24M-18.35M-12.78M-6.59M
Net Income-25.36M-24.05M-20.71M-18.29M-10.72M-6.65M
Balance Sheet
Total Assets45.70M46.72M41.91M53.41M60.98M55.46M
Cash, Cash Equivalents and Short-Term Investments10.60M12.22M19.82M28.43M38.74M43.94M
Total Debt5.87M6.01M5.49M5.86M6.11M4.45M
Total Liabilities37.53M35.29M19.99M21.48M21.56M15.23M
Stockholders Equity8.18M11.43M21.92M31.93M39.42M40.23M
Cash Flow
Free Cash Flow-7.96M-8.53M-9.51M-10.79M-4.34M-3.58M
Operating Cash Flow-7.93M-8.50M-9.14M-8.41M-2.95M-3.51M
Investing Cash Flow74.00K74.00K19.77M-22.09M-1.40M-70.90K
Financing Cash Flow299.00K297.00K81.00K220.00K547.41K17.34M

Stereotaxis Technical Analysis

Technical Analysis Sentiment
Positive
Last Price2.87
Price Trends
50DMA
2.39
Positive
100DMA
2.21
Positive
200DMA
2.18
Positive
Market Momentum
MACD
0.14
Negative
RSI
63.15
Neutral
STOCH
34.42
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For STXS, the sentiment is Positive. The current price of 2.87 is above the 20-day moving average (MA) of 2.61, above the 50-day MA of 2.39, and above the 200-day MA of 2.18, indicating a bullish trend. The MACD of 0.14 indicates Negative momentum. The RSI at 63.15 is Neutral, neither overbought nor oversold. The STOCH value of 34.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for STXS.

Stereotaxis Risk Analysis

Stereotaxis disclosed 57 risk factors in its most recent earnings report. Stereotaxis reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Stereotaxis Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
75
Outperform
$14.82B27.6511.38%1.28%-17.73%
74
Outperform
$5.27B45.258.60%10.14%0.04%
71
Outperform
$9.20B24.0715.36%1.29%1.51%21.70%
66
Neutral
$252.02M-198.62%33.94%-6.91%
61
Neutral
$1.88B-7.85%16.28%10.63%
56
Neutral
$1.36B55.81-25.55%-32.59%-667.81%
51
Neutral
$7.83B-0.18-40.10%2.29%21.46%-2.03%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
STXS
Stereotaxis
2.87
0.58
25.33%
ATR
AptarGroup
139.44
-11.12
-7.39%
ATRC
Atricure
37.30
11.48
44.46%
HOLX
Hologic
66.73
-14.03
-17.37%
MMSI
Merit Medical Systems
90.79
-5.21
-5.43%
STAA
Staar Surgical
27.51
-4.63
-14.41%

Stereotaxis Corporate Events

Private Placements and FinancingBusiness Operations and Strategy
Stereotaxis Announces $12.5M Stock Offering
Positive
Jul 17, 2025

On July 17, 2025, Stereotaxis announced a $12.5 million registered direct offering of common stock, priced at $2.00 per share, led by a strategic industry partner and select institutional investors. The company plans to use the proceeds to accelerate product commercialization, research and development, and other corporate purposes. The initial closing is expected on July 18, 2025, with proceeds of $8.5 million, and a second closing on November 25, 2025, for $4.0 million. This funding is expected to strengthen Stereotaxis’ balance sheet and support its innovation strategy.

Executive/Board ChangesShareholder Meetings
Stereotaxis Holds 2025 Annual Shareholders Meeting
Neutral
May 19, 2025

On May 15, 2025, Stereotaxis held its Annual Meeting of Shareholders, where a 59% quorum was achieved with 63,792,419 shares represented. During the meeting, shareholders elected two Class III directors to serve until the 2028 Annual Meeting and ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2025. The election of directors was determined by a plurality of votes, and the proposal to ratify the accounting firm was passed by a majority of the outstanding shares.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 19, 2025